Economic Evaluation of Chronic Diseases

Group leader: Marisa Merino Hernández, PhD.

Bidasoa IHO marialuisa.merinohernandez@osakidetza.eus
Dr. Marisa Merino is Managing Director of the Bidasoa Integrated Health Organization of Osakidetza. She is a Doctor of Medicine and Surgery, a specialist in Family and Community Medicine, a Master in Digital Health, an MBA, and an expert in Health Management with several postgraduate degrees. She is a regular teacher and collaborator in master’s degrees and courses at various universities such as the University of Deusto, the University of Alcalá, the Andalusian School of Public Health, the International University of Andalusia, the Open University of Catalonia or the University of the Basque Country. She is the director of the International Digital Health Congress held annually in San Sebastián, within the framework of the Summer Courses of the University of the Basque Country since 2014. Leader of various projects that have obtained multiple recognitions for management, quality and innovation in recent years. Vice president of the Signo Foundation, member of the board of directors of the ASD (Digital Health Association) and member of the board of directors of SEDISA (Spanish Society of Health Directors) in the Basque Country.

Objectives and lines

These are the main lines of work and their associated objectives:

Programme 1 P1: Evaluation of health policies.

This is a line of the epidemiological type related to measurement of the epidemiological and economic burden of chronic diseases, their determining factors and evaluation of the impact of their modification by health policies.

  • SP1 Measurement of the prevalence of dependence produced by chronic disease in the general population by means of mathematical models: ictus, acquired brain injury and Alzheimer’s disease.
  • SP2 Evaluation of the cost of disability associated to chronic disease: ictus, acquired brain injury and Alzheimer’s disease.
  • SP3 Total economic burden of chronic disease on the population: ictus, acquired brain injury and Alzheimer’s disease.
  • SP4 Evaluation of the impact on health and the economy of cancer screening programmes (breast and bowel) in the Basque Country.
  • SP5 Study and evaluation of the impact on the health of carers due to their work of caring for dependent elderly people.
  • SP6 Evaluation of the impact on health and costs of health policies aimed at reducing the consumption of salt and sugary drinks in the Spanish population.
  • SP7 Impact of osteoporosis treatments on the incidence of hip fractures.

Programme 2 P2: Evaluation of integrated organisational models for chronic diseases.

In our group we specify sub-programmes for patients with poly-pathology, pathology of the locomotor apparatus and cancer.

  • SP1 European CAREWELL project: Multi-level integration for patients with complex needs.
  • SP2 Evaluation of the application in Osakidetza of the integrated model of care for patients with poly-pathology.
  • SP3 Evaluation of an integrated model of care for pathology of the locomotor apparatus by means of discrete event simulation.
  • SP4 Studies of survival and costs of care in patients with prostate, bowel, breast and lung cancer.
  • SP5 Evaluation of an integrated model of health and social care for heart failure in the Alto Deba, Bajo Deba and Goierri-Alto Urola OHIs.

Programme 3 P3: Evaluation of health technologies

The economic evaluation methodology is complex due to requiring the use of mathematical models that represent the natural history of the disease. In the group we have a programme for evaluating interventions which has been applied to different treatments and diagnostic tests.

  • SP1 Use of thrombolysis treatment in the case of ictus.
  • SP2 Pharmacological treatment of hepatitis C with the new direct-acting antivirals
  • SP3 Diagnostic tests such as genetic testing aimed at predicting the risk of metastasis in breast cancer (Oncotype).
  • SP4 Evaluation of cost and quality of life in regard to using bariatric surgery in patients with morbid obesity
  • SP5 Population impact of hepatitis C treatment in Navarre

Team Members

Name Surname Center E-mail
Arantzazu Arrospide Elgarresta OSI Debagoiena arantzazu.arrospideelgarresta@osakidetza.eus
Iñigo Etxebarria Foronda OSI Debagoiena inigo.etxebarriaforonda@osakidetza.eus
Oliver Ibarrondo Olagüenaga OSI Debagoiena oliver.ibarrondoolaguenaga@osakidetza.eus
María Luz Jáuregui García OSI Tolosaldea marialuz.jaureguigarcia@osakidetza.eus
Myriam Soto Ruiz De Gordoa OSI Debagoiena myriamsotoruizdegordoa@osakidetza.eus
Uxue Zubiaguirre Iturbe OSI Debagoiena uxue.zubiaguirreiturbe@bio-gipuzkoa.eus

Scientific Output

CITA GO-ON: MODELO DE INTERVENCION MULTIMODAL DE PREVENCION DE DEMENCIA CENTRADO EN LA PERSONA, DIGITAL, INTERGENERACIONAL Y RENTABLE PARA GUIAR LAS POLITICAS ESTRATEGICAS QUE ENFRENTAN LOS DESAFIOS DEMOGRAFICOS DEL ENVEJECIMIENTO PROGRESIVO
Código: PLEC2021-008171
Investigador Principal (IP): JAVIER MAR MEDINA; MAIDER MATEO ABAD
Entidad Financiadora: MINISTERIO DE CIENCIA E INNOVACION
Fecha de Inicio: 2021-07-01
Fecha de finalización: 2025-09-30
Importe Concedido: 57.817,00 €
CARGA SOCIAL FORMAL Y SANITARIA DE LOS SINTOMAS NEUROPSIQUIATRICOS RELACIONADOS CON LA DEMENCIA: ESTUDIO DE REAL-WORLD DATA
Código: PI21/01405
Investigador Principal (IP): JAVIER MAR MEDINA; MARIA LUISA MERINO HERNANDEZ
Entidad Financiadora: ISCIII INSTITUTO DE SALUD CARLOS III
Fecha de Inicio: 2022-01-01
Fecha de finalización: 2024-12-31
Importe Concedido: 26.620,00 €